Effects of add-on ultramicronized N-palmitol ethanol amide in patients suffering of migraine with aura: A pilot study

Domenico Chirchiglia, Erika Cione, Maria C. Caroleo, Minyan Wang, Giulio Di Mizio, Noemi Faedda, Teodosio Giacolini, Serena Siviglia, Vincenzo Guidetti*, Luca Gallelli

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs. Methods: A total of 20 patients, 8 male (33-56-years, average 41.4 ± 7.8) and 12 female (19-61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment. Results: umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male P = 0.01189; female P = < 0.01) and they lasted until the end of the study (male P = 0.0066; female P = 0.01473). Conclusion: Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.

Original languageEnglish
Article number674
JournalFrontiers in Neurology
Issue numberAUG
Publication statusPublished - 17 Aug 2018


  • Clinical trial
  • Efficacy
  • Migraine with aura
  • Pain
  • Safety
  • Ultramicronized palmitoyl ethanol amide

Cite this